The drug transporter ABCB1 c.3435C>T SNP influences artemether–lumefantrine treatment outcome

Abstract Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria pat...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Kinanga Kiaco, António Sebastião Rodrigues, Virgílio do Rosário, José Pedro Gil, Dinora Lopes
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2017
Subjects:
Human polymorphism
CYP450
MDR1
Artemether–lumefantrine
Angola
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1186/s12936-017-2006-6
https://doaj.org/article/54118b330905434ca135e6f780f51845
Description
Summary:Abstract Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.

Similar Items